Defying the silent storm:
How AI can help with the detection and accelerated treatment of atherosclerotic disease
AI can detect high-risk atherosclerotic cardiovascular disease (ASCVD) patients and streamline their journey to treatment
Nearly 1 in 10 Americans suffer from ASCVD today.1 It is estimated that more than 50% of these patients are not on lipid-lowering therapy.2 Moreover, studies suggest that over 65% of patients who are on lipid-lowering treatment do not achieve a guideline-recommended cholesterol level.3 This high-risk group of patients are at a higher risk of a subsequent cardiovascular episode.
PCSK9 inhibitors offer an efficacious therapeutic solution for high risk patients — approximately 75% of the post-heart attack and post-stroke cohort, today only a quarter of ASCVD patients are getting their cholesterol levels checked post-ASCVD episode, and many of these patients are missing these guideline-supported therapies.4
1 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;Mar 17
2 Alexa C. Klimchak, Miraj Y. Patel, Şerban R. Iorga, Natasha Kulkarni, Nathan D. Wong,
Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States, American Journal of Preventive Cardiology, Volume 1, 2020
3 ACC TRANSFORM LDL-C Risk initiative
4 Sara N Levintow, Stephanie R Reading, Sina Noshad, Sophie E Mayer, Catherine Wiener, Bassim Eledath, Jason Exter & M Alan Brookhart (2022) Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008–2019, Clinical Epidemiology, 14:, 737-748.
An AI-powered Solution
Viz.ai is a comprehensive solution that not only detects high-risk ASCVD patients but also prevents patient fall-out. Through our seamless EHR integrations, Viz.ai empowers healthcare professionals and care teams to take immediate action at the point of care, facilitating prompt diagnosis and directing patients to optimal therapy. This represents the essence of AI-powered care coordination, which in turn leads to transformative improvements in patient outcomes. Accelerating time to therapy for high-risk ASCVD patients — we’re partnering with biopharma and medtech companies to enhance the patient journey to treatment.
Viz Connect offers provider workflows, directing cryptogenic stroke patients from neurology to cardiology. Many cryptogenic strokes have a cardiac origin therefore efficient care coordination is a critical process in the patient journey. Viz Connect customers report a 2 - 3x uplift in referrals to cardiology, ensuring patients receive appropriate follow-up diagnostic tests.
“There is a huge opportunity to streamline the patient journey for high-risk patients, ensuring they get appropriate follow up and access to the most efficacious therapies.”
Jack Manley, MD
Head of New Markets & Growth, Viz.ai